Picton Mahoney Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-150,000
Closed -$1.49M 1008
2021
Q3
$1.49M Hold
150,000
0.06% 429
2021
Q2
$1.49M Buy
+150,000
New +$1.51M 0.04% 438
2021
Q1
Sell
-200,000
Closed -$2.16M 392
2020
Q4
$2.16M Hold
200,000
0.1% 223
2020
Q3
$2.08M Hold
200,000
0.12% 192
2020
Q2
$2.01M Buy
+200,000
New +$1.99M 0.12% 176

Other funds holding STLN

Picton Mahoney Asset Management's STLN Position: Q4 2021 in Review

Picton Mahoney Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 150,000 shares — an estimated $1.49M sold.

Picton Mahoney Asset Management first reported a position in STLN in Q2 2020 and held it in 5 quarters. The position peaked at $2.16M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Picton Mahoney Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 150,000 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $1.49M.
  • Picton Mahoney Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
  • Picton Mahoney Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $2.16M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.